Lexaria CEO provides 2024 outlook; GLP-1 pilot shows DehydraTECH semaglutide benefit; IND filing imminent

Lexaria Bioscience Corp.

Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.
DehydraTECH semaglutide pilot (7 subjects) showed statistically higher drug proportion, faster absorption, fewer side effects vs Rybelsus.
FDA IND application for hypertension delayed ~5 months due to supplier; submission expected soon.
No debt taken in 2023 and no plan for debt in 2024; institutional holders rose to 19 with 1.8M shares.
R&D highlights: catestatin, inflammatory biomarkers, weight loss, blood glucose reduction, and nicotine study beating Zyn/On.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.